Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289990 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,705
- Enrollment target
NCT01289990: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT01289990 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,705 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (250% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01289990, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,705 participants
- Enrollment target
Study Summary
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
Primary Outcome
Change from baseline in HbA1c after 52 weeks
Interventions
- DRUG Placebo
- DRUG BI 10773
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,705 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01289990 record still lists
NCT01289990 is an interventional study that assigns participants to a tested intervention. Its 2,705 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (250% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01289990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01289990 about?
NCT01289990 is a clinical study titled "Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes". This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
What is the current status of trial NCT01289990?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,705 participants. The study started on 2011-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01289990?
The interventions under investigation include: Placebo (DRUG), BI 10773 (DRUG).
Who is sponsoring clinical trial NCT01289990?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01289990's enrollment target sits among peer trials
2,705 83rd of 2000 higher than 1,918 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia